Provided by Tiger Trade Technology Pte. Ltd.

ZYMEWORKS INC (US)

24.21
+0.03000.12%
Post-market: 23.79-0.4170-1.72%17:21 EDT
Volume:596.71K
Turnover:14.51M
Market Cap:1.79B
PE:-22.42
High:24.75
Open:24.09
Low:23.59
Close:24.18
52wk High:28.49
52wk Low:9.03
Shares:73.75M
Float Shares:38.30M
Volume Ratio:1.26
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0800
EPS(LYR):-1.0800
ROE:-26.72%
ROA:-14.29%
PB:6.65
PE(LYR):-22.42

Loading ...

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Benzinga_recent_news
·
Jan 08

Zymeworks Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer

Reuters
·
Jan 07

Zymeworks Inc. Held Annual Shareholder Meeting

Reuters
·
Dec 31, 2025

Celsius Holdings Among 3 Value Stocks Trading Below Estimated Worth

Simply Wall St.
·
Dec 30, 2025

Hasbro And 2 Other Stocks That May Be Priced Below Their Estimated Value

Simply Wall St.
·
Dec 30, 2025

Three Companies Estimated To Be Trading Below Their Intrinsic Value

Simply Wall St.
·
Dec 26, 2025

Discover 3 Stocks Including Atour Lifestyle Holdings That May Be Trading Below Estimated Value

Simply Wall St.
·
Dec 25, 2025

3 Stocks Estimated To Be Undervalued By Up To 48.3%

Simply Wall St.
·
Dec 20, 2025

Zymeworks Initiated at Buy by Truist Securities

Dow Jones
·
Dec 17, 2025

Zymeworks Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $40

THOMSON REUTERS
·
Dec 17, 2025

Truist Initiates Zymeworks at Buy With $40 Price Target

MT Newswires Live
·
Dec 17, 2025

Zymeworks Initiated at Market Outperform by Citizens

Dow Jones
·
Dec 04, 2025

Zymeworks Showcases Pipeline Advances at ASCO GI and J.P. Morgan Healthcare Conference

Reuters
·
Dec 03, 2025

Zymeworks (ZYME) Is Up 13.8% After Positive Zanidatamab Trial and Share Buyback Plan - What's Changed

Simply Wall St.
·
Nov 28, 2025

Zymeworks Inc. to Participate in Major Healthcare Investor Conferences

Reuters
·
Nov 24, 2025

LifeSci Capital Reaffirms Their Buy Rating on Zymeworks (ZYME)

TIPRANKS
·
Nov 22, 2025

Zymeworks price target raised to $40 from $37 at Leerink

TIPRANKS
·
Nov 20, 2025

A Look at Zymeworks (ZYME) Valuation After Breakthrough Phase 3 Cancer Trial Results

Simply Wall St.
·
Nov 20, 2025

Evercore ISI Sticks to Its Buy Rating for Zymeworks (ZYME)

TIPRANKS
·
Nov 19, 2025

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Medtronic (MDT)

TIPRANKS
·
Nov 19, 2025